Publication | Open Access

Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects

MedicineNovel TreatmentPharmacologyGynecologyReceptor-mediated Antiproliferative EffectsTumor TargetingAnti-cancer AgentCancer TreatmentOncologyImatinib MesylateEndocrine-related CancerOvarian Cancer